News
NCEL
2.490
-2.35%
-0.060
Weekly Report: what happened at NCEL last week (1026-1030)?
Weekly Report · 21h ago
Weekly Report: what happened at NCEL last week (1019-1023)?
Weekly Report · 10/26 09:57
Weekly Report: what happened at NCEL last week (1012-1016)?
Weekly Report · 10/19 09:57
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 10/15 12:12
Weekly Report: what happened at NCEL last week (1005-1009)?
Weekly Report · 10/12 10:00
Weekly Report: what happened at NCEL last week (0928-1002)?
Weekly Report · 10/05 10:00
Weekly Report: what happened at NCEL last week (0921-0925)?
Weekly Report · 09/28 09:56
Weekly Report: what happened at NCEL last week (0914-0918)?
Weekly Report · 09/21 09:57
NewcelX Files First-Half 2026 Results, Showing Wider Losses and Lower Cash
TipRanks · 09/18 21:01
NLS Pharmaceutics GAAP EPS of -$0.96
Seeking Alpha · 09/18 20:26
Weekly Report: what happened at NCEL last week (0907-0911)?
Weekly Report · 09/14 10:00
Weekly Report: what happened at NCEL last week (0831-0904)?
Weekly Report · 09/07 09:55
Weekly Report: what happened at NCEL last week (0824-0828)?
Weekly Report · 08/31 10:01
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 08/27 12:05
Weekly Report: what happened at NCEL last week (0817-0821)?
Weekly Report · 08/24 10:01
Closing Bell Movers: Ross Stores up 8% after earnings beat
TipRanks · 08/20 23:35
NewcelX registers to sell 694K common shares for holders
TipRanks · 08/20 20:20
Weekly Report: what happened at NCEL last week (0810-0814)?
Weekly Report · 08/17 10:02
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 08/14 12:06
Weekly Report: what happened at NCEL last week (0803-0807)?
Weekly Report · 08/10 09:58
More
Webull provides a variety of real-time NCEL stock news. You can receive the latest news about NewcelX Ltd through multiple platforms. This information may help you make smarter investment decisions.
About NCEL
NewcelX AG, formerly NLS Pharmaceutics AG, is a Switzerland-based company primarily engaged in the biotechnology industry. The Company focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The Company offers products like Quilience, which is a clinical-stage pharmaceutical compound. It aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The Company also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The Company is a publicly traded company, listing on the NASDAQ.